LYKA LABS LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 194 | 93 | 111 | 138 | 128 |
| EBITDA (ex other income) | 95 | 9 | 15 | 18 | (3) |
| margin % | 48.8 | 10.1 | 13.8 | 12.9 | (2.7) |
| Owners' profit | 0 | 0 | (3) | 8 | (10) |
| EPS, as reported (₹) | 13.57 | (4.63) | (0.79) | 2.22 | (2.81) |
| ROE % · ROCE % | 289.1 · 92.0 | (28.8) · (1.1) | (3.8) · 3.3 | 7.7 · 10.3 | (11.5) · (7.0) |
| Debt / equity (x) | 9.61 | 1.57 | 0.84 | 0.37 | 0.53 |
| Cash from operations | 79 | 9 | 2 | 2 | 5 |
| Capex | (8) | (8) | (9) | (16) | (11) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 34 | 33 | 33 | 37 | 31 | 28 | 42 |
| Profit before tax | 3 | 4 | 3 | 1 | (4) | (0) | (9) | 2 |
| Net profit | 2 | 3 | 2 | 1 | (3) | (0) | (8) | 2 |
| EPS (₹) | 0.58 | 0.75 | 0.49 | 0.25 | (0.94) | 0.00 | (2.13) | 0.57 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 12 Aug 2026 · Q1 FY26-27 results published in newspapers | compliance | minimal | — | — |
| 11 Aug 2026 · Lyka Labs 47th AGM: All 5 resolutions passed with 99.99 percent majority | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Lyka Labs Q1 FY27 revised results: Revenue up 45%, PAT up 159% | results | medium | — | — |
| 10 Aug 2026 · Lyka Labs 47th AGM proceedings - 5 ordinary resolutions passed | board shareholder meetings | medium | — | — |
| 10 Aug 2026 · Lyka Labs Q1 FY27: Net profit up 159 percent, exports surge 68 percent | compliance | low | — | — |
| 10 Aug 2026 · Q1 FY27 results: Rs 81 lakh profit, board approves Lyka BDR divestment | results | high | — | — |
| 10 Aug 2026 · Lyka Labs Q1 loss Rs 30 cr standalone, to divest Lyka BDR subsidiary | results | high | — | — |
| 24 Jul 2026 · Board meeting on 10 Aug to consider Q1 FY27 results | results | low | — | — |
| 20 Jul 2026 · Lyka Labs submits copies of newspaper ads for 47th AGM notice | compliance | minimal | — | — |
| 17 Jul 2026 · Lyka Labs 47th AGM on 10 Aug 2026; e-voting from 6 Aug | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 3.3 | 3.3 | 82 of 163 | 50% |
| ROCE | (9.8) | 10.8 | 168 of 183 | 8% |
| ROE | (11.5) | 10.4 | 163 of 171 | 5% |
| Debt / Equity | 0.5 | 0.1 | 145 of 171 | 15% |
| EBITDA margin | 11.7 | 17.5 | 111 of 165 | 33% |
| Revenue growth | 28.1 | 16.3 | 51 of 161 | 69% |
| Profit growth | 105.4 | 30.9 | 36 of 158 | 78% |
| Market cap | 300 | 839 | 107 of 182 | 41% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
